Logo.png
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th
April 29, 2021 08:00 ET | Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Logo.png
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting
April 17, 2021 08:00 ET | Avadel Pharmaceuticals plc
Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses DUBLIN, Ireland, April 17,...
Logo.png
Avadel to Present New Data from its Pivotal REST-ON Phase 3 Study of FT218 at the American Academy of Neurology Annual Meeting 2021
April 08, 2021 08:00 ET | Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 08, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Logo.png
Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on March 31st
March 18, 2021 08:00 ET | Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 18, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Logo.png
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 09, 2021 07:00 ET | Avadel Pharmaceuticals plc
New Drug Application (NDA) for once-nightly FT218 to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy accepted for filing by the FDA; assigned a Prescription Drug User Fee...
Logo.png
Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2021 Young Investigators Research Forum
March 04, 2021 08:00 ET | Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 04, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Logo.png
Avadel Pharmaceuticals Announces Publication of Once-Nightly FT218 Pharmacokinetic Studies
March 02, 2021 08:00 ET | Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Logo.png
Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
March 01, 2021 08:00 ET | Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 01, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s...
Logo.png
Avadel Pharmaceuticals to Participate in Fireside Chats at Upcoming March 2021 Investor Conferences
February 25, 2021 08:00 ET | Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Logo.png
Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th
February 23, 2021 18:20 ET | Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...